Summary
Atrial natriuretic factor, the first well defined natriuretic hormone is synthesized in the human heart as 151 aminoacid (AA) preprohormone and stored, as 126 AA prohormone in atrial ~anules. Ulbon apEropriate stimulation, the prohormone is cleaved into a 98 AA N-terminal tragment and a 28 AA C-terminal fragment, the biological active ANF(99-126), both circulating in plasma. Circulating ANF(99-126) is cleared by various organs, such as lung, liver and intestine, kidney and upper and lower limbs. Reported arterial-venous extraction ratios vary greatly, but are not much different between organs, the average extraction ratio being about 35 %. Due to marked differences of organ blood flow, the contributaon ot various organs to total body ANF clearance differs considerably. Major mechanisms for ANF clearance are uptake by clearance receptors and degradation by an endoprotease (E-C 3.4.24.11.). Clearance receptors, disrtinct from the receptors mediating the biological actions of ANF, have been demonstrateO in vg_rious organs. Characterization of the ANF degrad~g enzyme activity has been performed in kidney tissue. Whether and how pathophysiological states affect ANF clearance is still poorly understood. Inhibition of clearance by ANF analogues binding to clearance receptors and by inlaibitors of degrading peptidase can increase the biological action of circulating ANF. This may prove to be a therapeutic approach in diseases with smooth muscle contraction or volume overload.
Atrial natriuretic factor is the first well-defined natriuretic hormone. The best characterized pharmacological and partly physiological actions of ANF are natriuresis, diuresis and smooth muscle relaxation (for review see ref. 1-12). Recently, evidence has been provided that ANF might be involved in various other biological actions apart from its role in volume homeostasis such as immune or reproductive functions (13-17). ANF is synthesized in the human heart as a 151 amino acid pre-prohormone and stored as a 126 amino acid prohormone. Upon appropriate stimulation, such as atrial stretch, the prohormone is cleaved into an N-terminal and C-terminal fragment. The latter has been identified as the circulating bioactive ANF(99-126) (18, 19) . A body of investigations has concentrated on the mechanisms of ANF release and on its biologicalactions (for review 1-14). So far, there is much less information on the processing of ANF prohormone as well as on the clearance of bioactive ANF. However, these seem to be topms of considerable interest, since plasma levels and biological activity of ANF are significantly influenced by these processes. This review article wiI1 concentrate on the mechanisms of degradation and clearance of bioactive ANF, including pathophysiological aspects and possible therapeutic implications. The still poorly understood metabolism of ANF in the central nervous system will not be addressed in this article.
0024-3205/90 $3.00 + .00 Copyright (c) 1990 Pergamon Press plc Plasma levels of bioactive ANF are determined by both, release and clearance. While there is a rich body of information about ANF release, the number of studies on the clearance of tl~i. "s peptide is rather limited (20-36). The ability of various organs to clear ANT from the circulation can be describe.d by the extraction ratio or by the organ clearance. The extraction ratio is calculateO as arterial minus venous blood concentration over arterial blood con~ntration (%). Multiplication of the extraction ratio with the organ plasma flow results in the organ clearance Oiter/min). Several aspects and possible pitfalls have to be taken into consideration, regarding studies on ANF metabolism. Since the studies necessarily apply venous, and partly even arterial catheterization, for ethical reasons many investigattous have been done in patients with hypertension or congestive laeart failure rather than in healthy subjects. Some of the studies did not determine organ plasma flow, thus restricting their results to extraction ratios. Extraction ratios as well as organ clearance have been determined both under basal conditions and following intravenous ANF 8dmlnlstration. For clearance determinations of pharmacologically active ANT doses, specific attention should be paid to the rate of infusion in order to achieve steady state conditions. Problems may arise by inappropriate intervals of plasma s a .xn. pling. Furthermore, administration of ANF may decrease blood pressure (29) , affect carcliac output and organ blood flow and increase giomerular filtration rate; this might result in under-or overestimation of ANF clearance as compared to physiological conditions. Furthermore, some studies are based on the assumption, that there is no pulmonary extraction of ANF. However, there is now evidence obtained by pulmonary wedge or pulmonary venous sampling (20, 21) , that the lung is an important site for ANF extraction.
With these reservations in mind, it seems, that there is no major organ specificity for ANF extraction. Lung, liver, kidney, intestine and lower limb show similar extraction ratios within the respective studies. Values reported, however, differ considerably between various studies (Table 1) (20-24,26,27,29,31--34,36). Extraction ratios were reported to be 0% -33% for lung, 22% -75% for liver and intestine, 23% -67% for kidney and 15% -61% for the lower lfmb. Taken together, it seems, that there is a general arterio-venous organ extraction ratio for ANF of about 35%. Since there are marked differences of.organ blood flow, obviously total ANF clearance differs considerably between various organs. Few investigations have determined organ blood flow together with ANF extraction under physiological or steady-state conditions (20, 22, 24, 29) . About 50% of the total body clearance of ANF seems to be furnished by the lung (20). The renal (around 15%) (20,22,24) and splanchnic-hepatic (about 20%) (20,22,29) vascular beds also contribute significantly to ANF clearance. Several mechanisms could account for the above mentioned organ clearance of ANF: receptor-me0iatecl uptake, enzymatic degradation or organs celtic, excretion. (urine,. bile . However, there are onl%. few reports, of. concentrations of. ~a~ in bile (20) or urine (30,~5) . Therefore, organ specific excretion will not be covered m this article.
Enzymatic dem'adation
Since the kidney is a major target organ for ANF, interest has focussed on this organ not only as a site for receptor mediated clearance of this peptide, but also as a tissue which may be able to enzymaticaqly degrade circulating ANF(99-12ti). Peptidase degradation of ANF fs considered to play an important, role among possible clearance mechanisms. .
. (37, 38) . The brush border of the renal proximal tubule is known to be very nch m peptldases. These enzTmes are membrane bound and their active sites face the lumen of the tubule (39) . Incubating ANF(99-126) with these kidney microvilli results in a major degradation product cleaved between cysteine and phenylalanine (C'ys 105-Phe 106) (37, 38, (40) (41) (42) . Since the intact ring structure of ANF(99-126) is essential for its biological activity (43, 44) , ANF is effectively inactivated by this cleavage process.
The properties of the ANF degrading activity have been investigated by several groups. The responsl"ole substance is a glycoproteln (37, 40, 42) with a molecular wexght of approxtmately 94 kD, sensitive to metalloendoprotease inhibitors such as phosphoramidon and thiorphan. In view of these findings, the major proteolytic enzyme responsible for the ANF cleavage seems to be the endoprotease EC 3.4,24.11 (37, 40, 42) . EC 3.4.24.11 has been reported also to possess enkephaliri degrading activity. ~45). However, there may be various forms of EC 3.4.24.11, differing in cleavage site speL-ificity and tissue distributmn (40, (46) (47) (48) (49) (50) . Thus, one may speculate that the kidney p9ssesses a specific type of end oprotease EC 3.4.24.11. Apart from fhe major cleavage site within the loop structure, secondary attack by aminopeptidases has been hyp.othesized (37) . These e .n~cmes are not initially responsible for degradation, because spe~fic inhibitors like captopril o_r amastatin had no sighificant ettect (37). After the major cleavage process at the Cys-Phe bond of the ring structure, more complex degradation processes seem to follow, producing smaller ANF fragments (41) . The major sites of renaI ANF degradation by the endopepfidase seem to be the proximal tubule and the glomerulus (51) . Prompted by these observations, ettOrts have been made to develop ANF analogues, which are resistent to this enzyme, as well ..as specific enzyme inhibitors, which could be therapeutically employed. Recent reports indicate ANF degrading activity by the vasculature (52) and the adrenal capsule (46) .-No information is available about the enzymatic degradation activity of other organs reported to contribute to ANF clearance. In anesthetized rats, administration of an ANF analogue selectively binding to C-receptors, induced marked dose-dependent increases of ANF(99-126) plasma concentration, and decreases of its volume of distribution and metabolic clearance rate. Furthermore, there is evidence, that a major part of ANF metabolism is due to an internalization following the binding of circulating A.~F to the C-receptor and subsequent intralysomal hydrolysis (64) . The regulation of the C-receptor is poorly understood. There is evidence, that maneuvres decreasing intravascular volume decrease ANF plasma levels and in turn increase total ANF receptor density (70) (71) (72) . Surprisingly, this increase of ANF receptor density, is coupled to a reduced biological response to ANF. The observation, tlaat C-receptors but not Breceptors are augmented following dehydration (73) could explain this seeming contradiction and indicates that regulation of C-receptor density might be involved in volume homeostasis. There are few data on the quantitative relationship between B-and Creceptors in various tissues. In the kidney, in particular on glomeruli, the majority of ANF receptors seems to be of the clearance type (73, 74) . The same has been observed on cultured bovine aorta endothelial cells (56), on adrenal zona glomerulosa cells (74) and on lung membranes (61) . These recent observations are compatible with the concept of a functional importance of the C-receptors, which are distinctly different trom the Breceptors, in the clearance of ANF -a rather unique mechanism in the metabolism of peptldes.
Pathoohvsiolo~v
Elevated plasma concentrations of ANF have been found in various pathophysiological states, such as congestive heart failure, renal failure and in some patients with liver disease (e.g. [75] [76] [77] [78] ). An increased release of ANF h~ been suggested in these diseases (36, (79) (80) (81) (82) . However, elevated plasma concentrations might also be caused by decreased clearance. To date, little is known about clearance in pathophysiological states. Recently, it has been reported, that the fractional extraction of various organs is unchanged in patients with liver cirrhosis (27) . In an experimental model it has been shown that the renal clearance of ANF varies considerably, depending upon glomerular filtration rate (24); thus, augmented ANF plasma concentrations m renal diseases might be partly due to reduced ANF elimination. Tile proportion of B-and. C-receptors for ANF in aorta, adrenal and kidney seems unchanged in experimental congestive laeart failure (74) . In an experimental model of cirrhoms, C-receptor density on glomeruli was increased, whereas B-receptors tended to be decreased (83); however, these animals were not investigated for ANF clearance. Clearly, there is a need for further investigations on whether and how metabolic clearance and degradation of ANF is affected by pathophysiological states.
Theraueuti¢ implications
Beneficial effects of ANF application have been reported in congestive heart failure, hypertension, renal failure, clironic obstructive lung disease and liver disease (84-91 
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